MARKET

ADIL

ADIL

Adial Pharmaceuticals Inc
NASDAQ
1.120
+0.020
+1.82%
After Hours: 1.098 -0.022 -1.93% 18:00 06/21 EDT
OPEN
1.130
PREV CLOSE
1.100
HIGH
1.170
LOW
1.060
VOLUME
292.76K
TURNOVER
0
52 WEEK HIGH
14.00
52 WEEK LOW
0.7650
MARKET CAP
4.74M
P/E (TTM)
-0.2983
1D
5D
1M
3M
1Y
5Y
EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals announces publication of results from its Phase 3 ONWARD study. The company's lead asset, AD04, shows a significant difference in percentage of heavy drinking days among heavy drinking patients. The study was published in a peer-reviewed article in the European Journal of Internal Medicine.
Benzinga · 3d ago
Weekly Report: what happened at ADIL last week (0610-0614)?
Weekly Report · 6d ago
Weekly Report: what happened at ADIL last week (0603-0607)?
Weekly Report · 06/10 10:32
ADIAL PHARMACEUTICALS INC - TOPLINE RESULTS EXPECTED IN EARLY Q4 2024
Reuters · 06/05 12:33
EXCLUSIVE: Adial Pharmaceuticals Starts Patient Dosing In Pharmacokinetics Study Of AD04 For Alcohol Use Disorder
Adial Pharmaceuticals says first patient dosed in a pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinking patients. The study is expected to take six months to complete. Study will help company optimize design for upcoming Phase 3 clinical trial of the drug.
Benzinga · 06/05 12:00
Weekly Report: what happened at ADIL last week (0527-0531)?
Weekly Report · 06/03 10:34
Weekly Report: what happened at ADIL last week (0520-0524)?
Weekly Report · 05/27 10:37
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Sharps Technology (NASDAQ:STSS) shares rose to $ during Friday's after-market session. Cyclacel Pharmaceuticals and Adial Pharmaceuticals also moved upwards. Losers DIH Holding US and 60 Degrees stock fell during the session.
Benzinga · 05/24 20:31
More
About ADIL
Adial Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of treatments for addictions and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients. AD04 is investigated in the Company’s ONWARD pivotal Phase III clinical trial for the treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.

Webull offers Adial Pharmaceuticals Inc stock information, including NASDAQ: ADIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADIL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ADIL stock methods without spending real money on the virtual paper trading platform.